| Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration … L Kabasakal, M AbuQbeitah, A Aygün, N Yeyin, M Ocak, E Demirci, ... European journal of nuclear medicine and molecular imaging 42, 1976-1983, 2015 | 209 | 2015 |
| Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging E Demirci, OE Sahin, M Ocak, B Akovali, J Nematyazar, L Kabasakal Nuclear medicine communications 37 (11), 1169-1179, 2016 | 170 | 2016 |
| Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours L Kabasakal, E Demirci, M Ocak, C Decristoforo, A Araman, Y Ozsoy, ... European journal of nuclear medicine and molecular imaging 39, 1271-1277, 2012 | 159 | 2012 |
| Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging L Kabasakal, E Demirci, M Ocak, R Akyel, J Nematyazar, A Aygun, ... Nuclear medicine communications 36 (6), 582-587, 2015 | 153 | 2015 |
| 68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma E Demirci, M Ocak, L Kabasakal, C Decristoforo, Z Talat, M Halaç, ... European journal of nuclear medicine and molecular imaging 41, 1461-1462, 2014 | 142 | 2014 |
| The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer C Öbek, T Doğanca, E Demirci, M Ocak, AR Kural, A Yıldırım, U Yücetaş, ... European journal of nuclear medicine and molecular imaging 44, 1806-1812, 2017 | 131 | 2017 |
| Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607 M Ocak, A Helbok, C Rangger, PK Peitl, BA Nock, G Morelli, A Eek, ... European journal of nuclear medicine and molecular imaging 38, 1426-1435, 2011 | 99 | 2011 |
| EANM guideline on the validation of analytical methods for radiopharmaceuticals N Gillings, S Todde, M Behe, C Decristoforo, P Elsinga, V Ferrari, ... EJNMMI radiopharmacy and chemistry 5, 1-29, 2020 | 81 | 2020 |
| Lu-177-PSMA-617 prostate-specific membrane antigen inhibitor therapy in patients with castration-resistant prostate cancer: stability, bio-distribution and dosimetry L Kabasakal, T Toklu, N Yeyin, E Demirci, M Abuqbeitah, M Ocak, ... Molecular imaging and radionuclide therapy 26 (2), 62, 2017 | 79 | 2017 |
| FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection SY Aksoy, S Asa, M Ozhan, M Ocak, MS Sager, ME Erkan, M Halac, ... European journal of nuclear medicine and molecular imaging 41, 556-564, 2014 | 74 | 2014 |
| Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals N Gillings, O Hjelstuen, J Ballinger, M Behe, C Decristoforo, P Elsinga, ... EJNMMI radiopharmacy and chemistry 6, 1-22, 2021 | 72 | 2021 |
| 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update E Demirci, L Kabasakal, T Toklu, M Ocak, OE Sahin, N Alan-Selcuk, ... Nuclear medicine communications 39 (8), 789-796, 2018 | 69 | 2018 |
| Full automation of 68Ga labelling of DOTA-peptides including cation exchange prepurification M Ocak, M Antretter, R Knopp, F Kunkel, M Petrik, N Bergisadi, ... Applied Radiation and Isotopes 68 (2), 297-302, 2010 | 69 | 2010 |
| Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: preclinical evaluation E von Guggenberg, W Sallegger, A Helbok, M Ocak, R King, SJ Mather, ... Journal of medicinal chemistry 52 (15), 4786-4793, 2009 | 61 | 2009 |
| Guidance on validation and qualification of processes and operations involving radiopharmaceuticals BM Todde S,. Kolenc PeitlP., Elsinga P., Koziorowski J., Ferrari E V., Ocak ... EJNMMI Radiopharmacy and Chemistry 2 (8), 1-29, 2017 | 51 | 2017 |
| Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system M Petrik, PA Knetsch, R Knopp, G Imperato, M Ocak, E von Guggenberg, ... Nuclear Medicine Communications 32 (10), 887-895, 2011 | 43 | 2011 |
| Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer M Ocak, E Demirci, L Kabasakal, A Aygun, RO Tutar, A Araman, ... Nuclear medicine communications 34 (11), 1084-1089, 2013 | 38 | 2013 |
| The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels L Kabasakal, E Demirci, J Nematyazar, R Akyel, B Razavi, M Ocak, ... Nuclear Medicine Communications 38 (2), 149-155, 2017 | 37 | 2017 |
| Folate receptor-targeted multimodality imaging of ovarian cancer in a novel syngeneic mouse model M Ocak, AG Gillman, J Bresee, L Zhang, AM Vlad, C Müller, R Schibli, ... Molecular pharmaceutics 12 (2), 542-553, 2015 | 29 | 2015 |
| Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative M Ocak, A Helbok, E von Guggenberg, Y Ozsoy, L Kabasakal, L Kremser, ... Nuclear medicine and biology 38 (2), 171-179, 2011 | 27 | 2011 |
Emre DemirciYeditepe University Faculty of MedicineVerified email at yeditepe.edu.tr
